Alnylam completes enrollment in ENVISION phase 3 study of givosiran
Alnylam announced it has achieved full patient accrual in its ENVISION Phase 3 study of givosiran, an investigational RNAi therapeutic targeting aminolevulinic acid synthase 1 for treatment of acute hepatic porphyrias. Enrollment was completed with 94 AHP patients randomized across 36 sites. August 21, 2018